Can Ipilimumab restore immune response in advanced NSCLC after progression on anti‐PD‐1/PD‐L1 agents?
Anti‐PD‐1/PD‐L1 agents play a crucial part in the treatment of non‐small cell cancer (NSCLC) demonstrating improved overall response rate (ORR) and overall survival (OS). Recent studies evaluating combination treatment with anti‐PD‐1 and anti‐CTLA‐4 suggests improved outcome but also increased toxic...
Main Authors: | Michal Sternschuss, Nir Peled, Aaron M. Allen, Elizabeth Dudnik, Ofer Rotem, Noga Kurman, Omer Gal, Hiba Reches, Alona Zer |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-08-01
|
Series: | Thoracic Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1111/1759-7714.13502 |
Similar Items
-
Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
by: Valerie Glutsch, et al.
Published: (2019-07-01) -
Long-Term Remission with Ipilimumab/Nivolumab in Two Patients with Different Soft Tissue Sarcoma Subtypes and No PD-L1 Expression
by: Maggie Zhou, et al.
Published: (2021-03-01) -
CTLA-4 and PD-1 pathway Blockade : Combinations in the Clinic
by: Margaret Kathleen Callahan, et al.
Published: (2015-01-01) -
Successful Treatment of a Patient with anti-PD1 Antibody-Resistant Advanced Mucosal Melanoma with Nivolumab, Ipilimumab plus Denosumab Combination Therapy
by: Taku Fujimura, et al.
Published: (2020-03-01) -
Successful Treatment of Nivolumab-Resistant Multiple In-Transit Melanomas with Ipilimumab and Topical Imiquimod
by: Taku Fujimura, et al.
Published: (2018-01-01)